Most Read Articles
21 Dec 2019
There remains no single, convenient tool available for use as a gold standard in evaluation of quality of life in pruritus, a new study has shown.
Roshini Claire Anthony, 22 Jan 2020

A 300 mg QW or Q2W maintenance dupilumab regimen is less likely to result in worsening of atopic dermatitis (AD) than switching to a Q4W or Q8W regimen, results of the phase III LIBERTY AD SOLO-CONTINUE* trial show.

28 Nov 2019
The occurrence and severity of hidradenitis suppurativa (HS) are associated with micronutrient status and obesity, suggesting that weight loss and dietary modifications should be considered in the treatment of HS patients, according to the results of a systematic review and meta-analysis.
27 Nov 2019
Earlier-onset atopic dermatitis in children appears to correlate with stronger persistence over time and worse disease control, a recent study has found.

Ustekinumab use common in psoriasis

20 Dec 2019

Ustekinumab is the biologic therapy most commonly used among patients with psoriasis, though its survival is better among those who are treatment-naïve, a new study has shown.

Researchers conducted a retrospective analysis of 195 psoriasis patients (mean age at first biologic administration, 51.3±14.5 years; 65.6 percent male) who had moderate-to-severe disease. Treatment response was assessed according to the Psoriasis Area and Severity Index (PASI). Treatments that could sustain response for up to 4 months were deemed effective. The switching of biologic therapy was also documented.

Majority (90.6 percent) of the participants achieved a reduction of 75 percent in PASI scores (PASI 75); 72.6 percent and 68.4 percent achieved PASI 90 and PASI 100, respectively.

Ustekinumab was the most commonly used biologic agent in the study (27.8 percent; n=47), followed by etanercept, adalimumab, secukinumab and infliximab. More than half (54.9 percent; n=195) changed agents at least once; 32.3 percent (n=63) switched once, 12.3 percent (n=24) switched twice and 10.3 percent (n=20) switched at least thrice.

The median overall drug survival in treatment-naïve patients was highest for etanercept, at 3.2 years. This was followed by adalimumab (2.8 years) and infliximab (2.5 years). Survival calculations for ustekinumab and secukinumab were impossible due to their later entry to the market. In this subpopulation, ustekinumab had a survival of >7.0 years and secukinumab of >1.8 years.

In patients who had previously been treated, survival rates of the different biologics were comparable. However, each previously used biologic agent significantly increased the likelihood of a subsequent switch by 20 percent.

Editor's Recommendations
Most Read Articles
21 Dec 2019
There remains no single, convenient tool available for use as a gold standard in evaluation of quality of life in pruritus, a new study has shown.
Roshini Claire Anthony, 22 Jan 2020

A 300 mg QW or Q2W maintenance dupilumab regimen is less likely to result in worsening of atopic dermatitis (AD) than switching to a Q4W or Q8W regimen, results of the phase III LIBERTY AD SOLO-CONTINUE* trial show.

28 Nov 2019
The occurrence and severity of hidradenitis suppurativa (HS) are associated with micronutrient status and obesity, suggesting that weight loss and dietary modifications should be considered in the treatment of HS patients, according to the results of a systematic review and meta-analysis.
27 Nov 2019
Earlier-onset atopic dermatitis in children appears to correlate with stronger persistence over time and worse disease control, a recent study has found.